Mesenchymal Stromal Cells: Microenvironmental Modulators Become Cell Therapy

2021 ◽  
Author(s):  
Katarina Le Blanc ◽  
Mauro Krampera
Cytotherapy ◽  
2016 ◽  
Vol 18 (9) ◽  
pp. 1087-1099 ◽  
Author(s):  
Gabriela Ciapetti ◽  
Donatella Granchi ◽  
Caterina Fotia ◽  
Lucia Savarino ◽  
Dante Dallari ◽  
...  

2021 ◽  
Vol 28 (10) ◽  
pp. 1708-1725
Author(s):  
Mauro Krampera ◽  
Katarina Le Blanc

2018 ◽  
Vol 35 (06) ◽  
pp. 566-569 ◽  
Author(s):  
Bernard Thébaud

AbstractBronchopulmonary dysplasia remains the main complication of extreme preterm birth. Research over the past 10 years suggests the potential for stem cell-based therapies to prevent and/or restore organ damage in extreme preterm infants. Mesenchymal stromal cells, in particular, have advanced as the forerunner among various cell therapies based on very promising preclinical studies in animal models of neonatal lung injury. Early phase clinical trials are now underway to determine the safety and feasibility of this cell therapy in preterm infants at risk of developing bronchopulmonary dysplasia. This review will summarize the current rationale for testing mesenchymal stromal cells in this patient population and highlight the gaps in our knowledge to safely harness the full repair potential of cell-based therapies.


2017 ◽  
Vol 3 (3) ◽  
pp. 159-175
Author(s):  
Gaigai Li ◽  
Gaigai Li ◽  
Yang Hu ◽  
Yanfang Chen ◽  
Zhouping Tang ◽  
...  

Haematologica ◽  
2014 ◽  
Vol 99 (6) ◽  
pp. e94-e97 ◽  
Author(s):  
C. Capelli ◽  
O. Pedrini ◽  
G. Cassina ◽  
O. Spinelli ◽  
S. Salmoiraghi ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document